Back to top

oncology-screening: Archive

Zacks Equity Research

ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study

ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.

RHHBYPositive Net Change BMYPositive Net Change ALXONegative Net Change NRIXPositive Net Change

Zacks Equity Research

Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study

Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.

SNYPositive Net Change AZNPositive Net Change RHHBYPositive Net Change NRIXPositive Net Change

Zacks Equity Research

Agilent (A) is Set for Analytica 2024 With Advanced Products

Agilent (A) plans to showcase its new products for analytical laboratories at Analytica 2024, boosting its overall product portfolio.

APositive Net Change INCYPositive Net Change AMEPositive Net Change AMATNegative Net Change

Zacks Equity Research

Agilent (A) to Bolster DCG Segment With Upcoming Solutions

Agilent (A) plans to introduce new solutions for cancer research and diagnosis, boosting its DCG segment.

APositive Net Change AMEPositive Net Change AMATNegative Net Change BLPositive Net Change

Zacks Equity Research

Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why

Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.

PFEPositive Net Change ADMAPositive Net Change FGENNegative Net Change CRDFNegative Net Change